4

4. is definitely downregulated. The Mena isoform switching pattern described here may provide a Sele new biomarker for the presence of metastatic malignancy cells and for prognosis. Keywords:Breast tumor, Metastasis, Biomarker, Mena, Splice variant == Intro == Invasion of tumor cells into surrounding cells and intravasation into blood and lymphatic vessels is definitely implicated in the progression of metastatic mammary malignancy. This multistep process involves a number of phenotypic changes that happen sequentially and give rise to an invasive tumor cell capable of enhanced EGF stimulated motility and invasion [1]. In our effort to identify these individual events and to understand the molecular pathways underlying these phenotypic changes, we have developed animal models as well as a unique invasion assay that allows the isolation of invasive cells directly from the primary tumor and separates them from the average main tumor cells (APTC) [2]. Isolation of the invasive tumor cells and subsequent gene expression analysis resulted in the recognition of a specific gene expression signature in invasive tumor cells from mammary tumors of rats and mice called the invasion signature [3-5]. In several studies, a number of genes were recognized that must be coordinately up or downregulated in the invasive tumor cells in order for their invasion to lead to metastasis [3,6]. One of the important upregulated genes in invasive mammary tumor cells encodes the actin regulatory protein Mena, which we hypothesize to be a central switch point in the rules of the pathways encoded from the invasion signature. Mena is definitely a member of the Ena/VASP family, proteins that control the geometry of assembling F-actin networks and play a role in cell migration in a number of cell types and organisms [7]. They antagonize capping of actin filaments by capping proteins at their barbed ends and also reduce branching denseness through an unfamiliar mechanism [8,9]. The anti-capping activity of Mena has been proposed to amplify the barbed end output of the cofilin and Arp2/3 complex pathways, particularly in CRAC intermediate 2 response to EGF, which is sufficient to increase the metastatic potential of mammary tumors [1,7,10]. Ena/VASP proteins will also be constituents of the adherence junctions necessary to seal membranes in an epithelial sheet and control actin corporation on cadherin adhesion contact [11]. The stability of cadherens junctions is frequently perturbed in invasive tumor cells and Mena may play a role with this transition to invasion. Ena/VASP proteins share a conserved website structure including the N-terminal EVH1 (Ena/VASP Homology) website, that plays an essential part in intracellular protein localization by interacting with FP4 motifs found in proteins such as zyxin and vinculin [12]. The LIM3 website of the tumor suppressor Tes binds specifically to Mena EVH1 and competes with FP4-comprising proteins for connection with Mena [13]. The central proline-rich region mediates connection with proteins comprising SH3 and WW domains and with the actin monomer binding protein profilin [8]. The C-terminal EVH2 website binds to G and F-actin and contains a coiled-coil that mediates formation of stable tetramers [14]. The connection of the EVH2 website with the growing ends of the actin filaments is essential for focusing on the Ena/VASP to lamellipodia [15]. Upregulation of Mena mRNA manifestation in both mouse and rat invasive mammary malignancy cells [3,4] is consistent with the observed increased manifestation of Mena protein in human breast cancer cells and malignancy cell lines [16-18]. These observations, and the proposed central part of Mena in regulating invasion and metastasis [1], prompted us to look deeper into this manifestation pattern and the pattern of manifestation of Mena splice variants in particular. Previously, mouse and human being Mena homologs have been cloned, sequenced and a number of splice variants have been recognized [8,19]. Recently it has been demonstrated that splice variants can work very efficiently as malignancy biomarkers [20,21]. Our study goal was to identify any known or fresh splice variants of Mena that are up or downregulated specifically in invasive mammary malignancy cells. The value of such info would be in the design of fresh molecular probes (either nucleic acid CRAC intermediate 2 or protein) to identify metastatic tumor cells in vivo. == Methods == == Isolation of invasive tumor cells using the in vivo invasion assay and fluorescence-activated cell sorting of tumor cells at different phases of the metastasis == All CRAC intermediate 2 methods including rats and mice were conducted in accordance with.